Celltrion

Private Equity Steps up for Baxter Biopharma

A private equity consortium of Warburg Pincus and Advent International is said to be in advanced talks to acquire medical device maker Baxter International’s biopharma solutions business. The deal could be worth $4 billion or more, news agencies and the newspaper Wall Street Journal reported.

Baxter Said to Eye Sale of Biopharma CMO Arm

Plans by US healthcare company Baxter International to shed its biopharma contract business as it streamlines operations after a poor 2022 earnings performance are gradually taking concrete shape.

Lonza to Produce Biosimilar for Celltrion

Mundipharma to Launch Biosimilar Truxima in Europe

The Biosimilar Market

European Medicines Agency Pave Way for Biosimilar Drug Breakthrough